Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Orchestra BioMed Holdings (OBIO) Short term Debt (2022 - 2023)

Orchestra BioMed Holdings (OBIO) has disclosed Short term Debt for 2 consecutive years, with $9.6 million as the latest value for Q3 2023.

  • Quarterly Short term Debt changed N/A to $9.6 million in Q3 2023 from the year-ago period, while the trailing twelve-month figure was $9.6 million through Sep 2023, changed N/A year-over-year, with the annual reading at $2.1 million for FY2022, N/A changed from the prior year.
  • Short term Debt for Q3 2023 was $9.6 million at Orchestra BioMed Holdings, up from $2.1 million in the prior quarter.
  • The five-year high for Short term Debt was $9.6 million in Q3 2023, with the low at $2.1 million in Q4 2022.